Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

Sanofi breached ABPI Code over unsubstantiated β€œfewer prescriptions” claim for Toujeo DoubleStar in virtual promo meeting

Sanofi’s Toujeo DoubleStar slide deck wrongly claimed β€œfewer prescriptions”. PMCPA ruled the claim misleading and unsubstantiated, and found…

8 Mar 2026

Sanofi: uncertified advocacy planning templates treated as reps’ briefing material (Toujeo) (AUTH/3559/9/21)

Anonymous employee alleged Toujeo/Suliqua β€œadvocate” programme induced prescribing and misused HCP data. Panel found no inducement/GDPR breach, but…

8 Mar 2026

Novartis Entresto podcast: unsubstantiated β€˜energy’ claim, β€˜best’ implied superiority, and renal safety downplayed (AUTH/3635/4/22)

PMCPA found Novartis breached the ABPI Code over an Entresto nurse podcast: an unsubstantiated β€˜energy’ claim, β€˜best’ implying…

8 Mar 2026

AstraZeneca v GSK: Trelegy COPD NMA headline claim ruled misleading (AUTH/3699/10/22)

GSK’s HCP webpage/video used an NMA to headline β€œgreater exacerbation reduction” vs other COPD SITTs. PMCPA ruled the…

8 Mar 2026

AUTH/3823/9/23: GSK LinkedIn β€˜likes’ on US momelotinib approval posts – no breach (Clauses 12.1, 12.10, 26.1)

Complaint alleged GSK staff β€˜likes’ on LinkedIn posts about US FDA approval of momelotinib promoted a POM to…

8 Mar 2026

AUTH/3923/6/24: Complainant v GSK β€” Trelegy sales aid alleged off-label promotion (No breach)

Anonymous health professional alleged GSK sales aids promoted Trelegy for patients inadequately treated on multiple-inhaler triple therapy (MITT).…

8 Mar 2026

AUTH/2141/7/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (24-hour efficacy and hypoglycaemia claims)

Complaint about Lantus promotional leavepieces and a mailer. Issues included β€œ24-hour efficacy” wording and comparative hypoglycaemia claims based…

8 Mar 2026

AUTH/2176/10/08: Nurse v Schering-Plough β€” alleged confidentiality breach in NHS infusion service programme (No breach)

A nurse alleged she was suspended for refusing to share confidential unit/customer data from an infusion service facilitation…

8 Mar 2026

AUTH/2289/12/09: Merck Sharp & Dohme v Alcon β€” Azarga β€œcomfort” leavepiece and over-emphasis claims

Alcon’s Azarga leavepiece repeatedly used β€œcomfort/comfortable”. Appeal Board allowed the comparative β€œSignificantly more comfortable than Cosopt” claim (with…

8 Mar 2026

AUTH/2979/9/17: Anonymous non-contactable complainant v PharmaMar

PMCPA case summary: Anonymous non-contactable complainant vs PharmaMar (AUTH/2979/9/17). Case details, clauses, outcome and sanctions were not stated…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training